OLYMPIA-3: A phase 3 trial of odronextamab in people with diffuse large B-cell lymphoma

This trial is testing the treatment odronextamab in adults with diffuse large B-cell lymphoma (DLBCL) who have not yet received any previous treatment, who have disease that has come back after treatment (relapsed), or who have not responded to treatment (refractory).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06091865

Trial aim and background  

The aim of this trial is to find out how the medication odronextamab, when given with chemotherapy, compares to current treatment options. It will be given to patients with DLBCL who have not yet received any treatment or who have relapsed or refractory disease.

It will be made up of two parts: part 1 aims to see how safe and well tolerated the treatment is, as well as establishing the correct dose and schedule. The second part aims to see effective it when compared with the current standard of care treatment.

Amongst other things the study aims to look at:

  • What side effects the treatment has
  • Whether your body makes antibodies against the treatment
  • Whether the treatment impacts on your quality of life

Odronextamab is a bispecific antibody. This is a type of targeted treatment which sticks to two different target proteins, one on lymphoma cells and one on healthy T cells. This helps the T cells find and destroy the lymphoma cells.

Who can enter 

Adults with previously untreated or, relapsed or refractory DLBCL may be eligible for this trial.

Locations 

Recruitment is taking place at NHS Grampian, Aberdeen Royal Infirmary, Aberdeen

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06091865


Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.